StreetInsider.com News Articles

Form 4 RESMED INC For: Sep 02 Filed by: FARRELL PETER C

Fri, 04 Sep 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20260904/27027426.html

Form 144 RESMED INC Filed by: FARRELL PETER C

Wed, 02 Sep 2026 19:16:00 -0400

si-local-file:///var/storage/secattach/20260902/27020663.html

Form 8-K RESMED INC For: Aug 31

Tue, 01 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260901/27013287.html

Frazier Healthcare buys MatrixCare from ResMed, names new CEO

Tue, 01 Sep 2026 08:30:33 -0400

Frazier Healthcare Partners has completed its acquisition of MatrixCare from ResMed (NYSE & ASX: RMD), according to a press release from the Seattle-based private equity firm.

MatrixCare provides cloud-based electronic health record and revenue cycle management software to more than 15,000 providers in skilled nursing, senior living, home health, hospice, and life plan communities.

Concurrent with the closing, Jonathan Lujan has been appointed Chief Executive Officer of MatrixCare. Lujan previously served as CEO of Sight Growth Partners and held executive roles at DaVita, Surgical Information Systems, GE Healthcare, and J.P. Morgan's Healthcare Investment Banking Group.

"MatrixCare has built a trusted platform with a

Frazier Healthcare Partners Completes Acquisition of MatrixCare, Appoints Jonathan Lujan as Chief Executive Officer

Tue, 01 Sep 2026 08:30:00 -0400

Healthcare Technology Executive to Lead MatrixCare's Next Phase of Growth and Product Innovation

SEATTLE--(BUSINESS WIRE)-- Frazier Healthcare Partners ("Frazier"), a private equity firm focused exclusively on the healthcare industry, today announced the closing of its acquisition of MatrixCare (the "Company") from Resmed (NYSE & ASX: RMD).

MatrixCare is a leading provider of cloud-based electronic health record (“EHR”) and revenue cycle management (“RCM”) solutions purpose-built for out-of-hospital care settings, including skilled nursing, senior living, home health, hospice, and life plan communities. A multi-year winner of the Best in KLAS award, MatrixCare is used by thousands of facility-based and home-based

Frazier Healthcare Partners Completes Acquisition of MatrixCare, Appoints Jonathan Lujan as Chief Executive Officer

Tue, 01 Sep 2026 08:30:00 -0400

Healthcare Technology Executive to Lead MatrixCare's Next Phase of Growth and Product Innovation

ResMed (RMD) PT Raised to $267 at KeyBanc Following Last Week's NDR

Mon, 31 Aug 2026 08:45:57 -0400

(Updated - August 31, 2026 8:45 AM EDT)

KeyBanc analyst Brett Fishbin raised the price target on ResMed (NYSE: RMD) to $267.00 (from $255.00) while maintaining an Overweight rating.

The analyst commented: "Raising PT to $267 Following Last Week's NDR; Reiterate OW and raise PT to $267 (from $255); we walked away from our NDR incrementally comfortable with RMD's FY27 outlook, and believe there could be room for further sentiment recovery. More specifically: 1) mgmt. appeared confident in FY27 visibility, as well as the runway toward 2030 targets; 2) we acknowledge valuation overhangs including Astral, U.S. competitive dynamics (PHG), and GLP-1s, but

ResMed (RMD) PT Raised to $267 at KeyBanc Following Last Week's NDR

Mon, 31 Aug 2026 08:45:57 -0400

(Updated - August 31, 2026 8:45 AM EDT)

KeyBanc analyst Brett Fishbin raised the price target on ResMed (NYSE: RMD) to $267.00 (from $255.00) while maintaining an Overweight rating.

Rothschild Redburn Starts ResMed (RMD) at Neutral

Wed, 19 Aug 2026 04:05:36 -0400

Rothschild Redburn analyst Jackson Philips initiates coverage on ResMed (NYSE: RMD) with a Neutral rating and a price target of $230.00.

The analyst comments: “Resmed is the market-leading provider of a gold standard treatment in an underpenetrated obstructive sleep apnoea (OSA) market. We see a potential volume runway for continuous positive airway pressure (CPAP) as a treatment for OSA, but structural barriers remain, and we note inflection is dependent on several swing factors including the impact of glucagon-like peptide-1 (GLP-1) pharmaceuticals, wearable consumer health devices and at-home diagnostics. While Resmed benefits from deep moats, sector-leading margins and a net cash balance

Rothschild Redburn Starts ResMed (RMD) at Neutral

Wed, 19 Aug 2026 04:05:36 -0400

Rothschild Redburn analyst Jackson Philips initiates coverage on ResMed (NYSE: RMD) with a Neutral rating and a price target of $230.00.

Form 8-K RESMED INC For: Aug 13

Mon, 17 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26938376.html

Form 8-K RESMED INC For: Aug 13

Mon, 17 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26938376.html

ResMed names Carol Burt as lead director as Ron Taylor retires

Mon, 17 Aug 2026 16:11:06 -0400

ResMed (NYSE: RMD, ASX: RMD) announced that Carol Burt will become Lead Director on November 15, 2026, succeeding Ron Taylor, who will retire after more than 21 years of service on the company's board.

Burt has served on ResMed's board since 2013 and currently chairs the Nominating and Governance Committee. She also serves on the Audit Committee and the Compliance, Privacy and Quality Committee. Her appointment as Lead Director takes effect three days before ResMed's 2026 Annual Meeting of Stockholders, scheduled for November 18, 2026.

Taylor joined ResMed's board in 2005 and has served as Lead Director since 2013. He will not

Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor